Table 5.
Association between BRCA1 and BRCA2 mutation carriers and breast cancer pathology
| BRCA Mutations‡ | ||||||||
|---|---|---|---|---|---|---|---|---|
| BRCA1 (n = 15) | BRCA2 (n = 22) | Unadjusted | ||||||
| n | Col % | n | Col % | χ2 | P-value | OR† | 95% CI | |
| LVI (Lymphatic invasion): | ||||||||
| Absent/suspiciousa | 9 | 90.0 | 11 | 91.7 | 1.00** | |||
| Present | 1 | 10.0 | 1 | 8.3 | 0.02 | 0.89 | 1.22 | (0.07, 20.00) |
| Grade: | ||||||||
| 2 | 4 | 36.4 | 5 | 38.5 | 1.00** | |||
| 3 | 7 | 63.6 | 8 | 61.5 | 0.01 | 0.92 | 1.10 | (0.17,4.81) |
| Type: | ||||||||
| DCIS (Ductal carcinoma In Situ) | 1 | 7.7 | 7 | 33.3 | 1.00** | |||
| Invasive | 12 | 92.3 | 14 | 66.7 | 2.93 | 0.09 | 6.00 | (0.65, 50.00) |
| Stage: | ||||||||
| Stage 0 | 1 | 8.3 | 7 | 36.8 | ||||
| Stage 1 | 5 | 41.7 | 5 | 26.3 | 1.00** | |||
| Stage 2, 3 | 6 | 50.0 | 7 | 36.8 | 1.28 | 0.86 | 1.17 | (0.22, 6.08) |
| T stage (Tumor size): | ||||||||
| T0 | 1 | 7.7 | 7 | 35.0 | ||||
| T1 | 5 | 38.5 | 11 | 55.0 | 1.00** | |||
| T2 | 7 | 53.8 | 2 | 10.0 | 7.52 | 0.04 | 7.69 | (1.16, 5.00) |
| N stage (Lymph node involvement) | ||||||||
| N0 | 11 | 91.7 | 11 | 64.7 | 1.00** | |||
| N1 and 2 | 1 | 8.3 | 6 | 35.3 | 2.89 | 0.12 | 0.17 | (0.02,1.61) |
| ER (Estrogen receptor): | ||||||||
| Positive | 3 | 25.0 | 12 | 63.2 | 1.00** | |||
| Negative | 9 | 75.0 | 7 | 36.8 | 4.29 | 0.04 | 5.14 | (1.03, 25.60) |
| PR (Progesterone receptor): | ||||||||
| Positive | 3 | 25.0 | 8 | 44.4 | 1.00** | |||
| Negative | 9 | 75.0 | 10 | 55.6 | 1.17 | 0.28 | 2.40 | (0.48, 11.93) |
| Cerb 2 (Protein of HER2 Oncogene): | ||||||||
| Positive | 4 | 33.3 | 5 | 29.4 | 1.00** | |||
| Negative | 8 | 66.7 | 12 | 70.6 | 0.05 | 0.82 | 0.83 | (0.17, 4.09) |
| Triple negative (ER − /PR − /Cerb2 −): | ||||||||
| No | 4 | 33.3 | 11 | 64.7 | 1.00** | |||
| Yes | 8 | 67.7 | 6 | 35.3 | 2.77 | 0.10 | 3.67 | (0.77, 17.43) |
| Ki67 index (% of growing cells): | ||||||||
| <12% | 1 | 100.0 | 5 | 55.6 | ||||
| >12% | 0 | 0.0 | 4 | 44.4 | 0.74 | 0.39 | – | – |
aThere were only two BRCA2 with LVI suspicious
Bold figure: P-value <0.05
* Values may not sum to 100% because of missing data
** Referent
‡ Includes 4 bilateral cancers in BRCA1 mutation carriers (27%) and 5 bilateral cancers in BRCA2 mutation carriers (23%)
† Univariate Odd Ratios comparing “Carriers” versus “Non-carriers” (reference group)